A novel aldehyde reductase with activity towards a metabolite of aflatoxin B1 is expressed in rat liver during carcinogenesis and following the administration of an anti-oxidant

David J. Judah, John D. Hayes, Ji-Chun Yang, Lu-Yun Lian, Gordon C. K. Roberts, Peter B. Farmer, J H Lamb, Gordon E. Neal

Research output: Contribution to journalArticle

74 Citations (Scopus)


In contrast with fractions from control animals, an aldehyde reductase, which catalyses the reduction of aflatoxin B1-dihydrodiol, in the dialdehyde form at physiological pH values, to aflatoxin B1-dialcohol, is expressed in cytosolic fractions prepared from rat livers bearing pre-neoplastic lesions, or following treatment with the anti-oxidant ethoxyquin. This expression parallels the development of resistance to the toxin. Unlike the aflatoxin B1-dihydrodiol, the dialcohol does not undergo binding to protein. This enzyme activity could play a mechanistic role in hepatocarcinogenesis and chemoprotection in the rat. Correlated n.m.r. and m.s. spectra are provided in Supplementary Publication SUP 50171 (3 pages), which has been deposited at the British Library Document Supply Centre, Boston Spa, Wetherby, West Yorkshire LS23 7BQ, U.K., from whom copies can be obtained on the terms indicated in Biochem. J. (1993) 289, 9.

Original languageEnglish
Pages (from-to)13-8
Number of pages6
JournalBiochemical Journal
Issue number1
Publication statusPublished - 15 May 1993



  • Aflatoxin B1/metabolism
  • Aldehyde Reductase/metabolism
  • Animals
  • Ethoxyquin/pharmacology
  • Liver/drug effects
  • Liver Neoplasms, Experimental/enzymology
  • Precancerous Conditions/enzymology
  • Rats
  • Rats, Inbred F344
  • Substrate Specificity

Cite this